Redesign Science

0 followers


Redesign Science develops and applies a molecular dynamics-driven platform for in silico drug discovery against emerging drug target classes. We work in partnership with Biotech and Pharma to co-develop novel small molecule therapeutics.

Industries

Employees

11-50

Links

Org chart

David Rooklin

Collapse
Andrew Avorn
General Counsel
Sharon Blaettler
Head Of Biology
Scott Liu
Director of Business Development
欢 刘
Director
Janan Zhu
Head of Engineering